Sonoma Pharmaceuticals’ (SNOA) Sell (D-) Rating Reiterated at Weiss Ratings

Sonoma Pharmaceuticals (NASDAQ:SNOA)‘s stock had its “sell (d-)” rating reaffirmed by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded shares of Sonoma Pharmaceuticals to a “hold” rating in a research report on Friday, October 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Sonoma Pharmaceuticals Trading Down 1.9%

Shares of Sonoma Pharmaceuticals stock opened at $4.17 on Wednesday. Sonoma Pharmaceuticals has a 1 year low of $1.75 and a 1 year high of $6.92. The firm has a market capitalization of $6.84 million, a PE ratio of -1.70 and a beta of 1.46. The firm’s 50 day moving average is $4.19 and its 200 day moving average is $3.45.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.14. Sonoma Pharmaceuticals had a negative net margin of 23.87% and a negative return on equity of 50.00%. The firm had revenue of $4.01 million during the quarter, compared to analysts’ expectations of $4.26 million. As a group, research analysts anticipate that Sonoma Pharmaceuticals will post -0.67 earnings per share for the current year.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Heron Bay Capital Management acquired a new position in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 33,782 shares of the company’s stock, valued at approximately $96,000. Heron Bay Capital Management owned 2.06% of Sonoma Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.